Intellia Therapeutics Announces Upcoming Investor Event to Present Interim Clinical Data from Ongoing First-in-Human Studies of NTLA-2002 and NTLA-2001 on September 16, 2022
September 08 2022 - 3:01PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage
genome editing company focused on developing potentially curative
therapeutics leveraging CRISPR-based technologies, today announced
that it will host a virtual investor event to present interim data
from the first-in-human clinical studies of NTLA-2002 and NTLA-2001
on September 16, 2022, at 8:00 a.m. ET.
NTLA-2002 First Interim Clinical Data Review
Intellia will review the interim clinical data from the Phase 1/2
study of NTLA-2002 for the treatment of hereditary angioedema
(HAE), which is scheduled to be presented at the 2022 Bradykinin
Symposium on September 16 in Berlin, Germany. The presentation will
focus on the initial safety, kallikrein protein reduction and HAE
attack rate data from the dose-escalation portion of the study.
NTLA-2002 is Intellia’s wholly owned, second systemically
administered in vivo CRISPR candidate.
NTLA-2001 Interim Clinical Data Update from the
Cardiomyopathy ArmIntellia will present interim clinical
data from the ongoing Phase 1 study of NTLA-2001 for the treatment
of transthyretin (ATTR) amyloidosis. The study update will focus on
the dose-escalation portion of the cardiomyopathy arm of the study.
The event will include a presentation by Julian Gillmore, M.D.,
Ph.D., FRCP, FRCPath, Professor of Medicine, National Amyloidosis
Centre, UCL Division of Medicine, Royal Free Hospital, U.K., the
trial’s national coordinating investigator. NTLA-2001, which is
being developed as part of a multi-target collaboration with
Regeneron, is being evaluated in patients with either ATTR
amyloidosis with polyneuropathy (ATTRv-PN) or ATTR amyloidosis with
cardiomyopathy (ATTR-CM).
To join the webcast on September 16, 2022, at 8:00 a.m. ET,
please visit this link, or the Events and Presentations page of the
Investors & Media section on Intellia’s website at
www.intelliatx.com. A replay of the events will be available
through the Events and Presentations page of the Investors &
Media section on Intellia’s website for at least 30 days following
the event.
About NTLA-2002 Based on Nobel
Prize-winning CRISPR/Cas9 technology, NTLA-2002 is the first
single-dose investigational treatment being explored in clinical
trials for the potential to continuously reduce kallikrein activity
and prevent attacks in people living with hereditary angioedema
(HAE). NTLA-2002 is a wholly owned investigational CRISPR
therapeutic candidate designed to inactivate the kallikrein B1
(KLKB1) gene, which encodes for prekallikrein, the kallikrein
precursor protein. NTLA-2002 is Intellia’s second
investigational CRISPR therapeutic candidate to be administered
systemically, by intravenous infusion, to edit disease-causing
genes inside the human body with a single dose of treatment.
Intellia’s proprietary non-viral platform deploys lipid
nanoparticles to deliver to the liver a two-part genome
editing system: guide RNA specific to the disease-causing
gene and messenger RNA that encodes the Cas9 enzyme, which
together carry out the precision editing.
About NTLA-2001Based on Nobel
Prize-winning CRISPR/Cas9 technology, NTLA-2001 could potentially
be the first single-dose treatment for ATTR amyloidosis. NTLA-2001
is the first investigational CRISPR therapy candidate to be
administered systemically, or through a vein, to edit genes inside
the human body. Intellia’s proprietary non-viral platform deploys
lipid nanoparticles to deliver to the liver a two-part genome
editing system: guide RNA specific to the disease-causing
gene and messenger RNA that encodes the Cas9 enzyme, which
carries out the precision editing. Robust preclinical data, showing
deep and long-lasting transthyretin (TTR) reduction following in
vivo inactivation of the target gene, supports NTLA-2001’s
potential as a single-administration therapeutic. Intellia leads
development and commercialization of NTLA-2001 as part of a
multi-target discovery, development and commercialization
collaboration with Regeneron.
About Intellia TherapeuticsIntellia
Therapeutics, a leading clinical-stage genome editing company, is
developing novel, potentially curative therapeutics leveraging
CRISPR-based technologies. To fully realize the transformative
potential of CRISPR-based technologies, Intellia is pursuing two
primary approaches. The company’s in vivo programs use
intravenously administered CRISPR as the therapy, in which
proprietary delivery technology enables highly precise editing of
disease-causing genes directly within specific target tissues.
Intellia’s ex vivo programs use CRISPR to create the therapy by
using engineered human cells to treat cancer and autoimmune
diseases. Intellia’s deep scientific, technical and clinical
development experience, along with its robust intellectual property
portfolio, have enabled the company to take a leadership role in
harnessing the full potential of genome editing to create new
classes of genetic medicine. Learn more at intelliatx.com. Follow
us on Twitter @intelliatx.
Intellia Contacts:
Investors:Ian KarpSenior Vice President,
Investor Relations and Corporate
Communications+1-857-449-4175ian.karp@intelliatx.com
Lina LiSenior Director, Investor Relations and Corporate
Communications+1-857-706-1612lina.li@intelliatx.com
Media:Rebecca SpaldingTen Bridge
Communications+1-646-509-3831media@intelliatx.comrebecca@tenbridgecommunications.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024